Hints and tips:
...CSL Behring’s Hemgenix, a gene therapy targeting the same disease, is also priced at $3.5mn....
...Last month the US Food and Drug Administration approved Hemgenix, which was developed by CSL Behring and UniQure and is delivered via a single dose though intravenous infusion....
...The site supports around 6,000 jobs and is home to the likes of GSK and CSL Behring....
...The Anglo-Australian group said on Wednesday it had hired David Lamont from CSL Behring, a fast-growing biotechnology company that in March briefly overtook BHP as Australia’s most valuable listed company...
...Bill Mezzanotte, executive vice-president at CSL Behring, another company working on the approach, said: “Everybody recognises the need to re-engineer the process....
...“Plasma product demand is growing faster than supply,” said Ben Yang, China general manager for CSL’s US subsidiary CSL Behring....
...Shire has been trying to defend market share for its Cinryze injection, which costs about $300,000 per patient per year and is facing new competition from CSL Behring....
...We believe that CSL [Behring], Baxalta/Shire and Bayer are disqualified based on anti-trust reasons and we also believe that neither CSL nor Baxalta/Shire have the financial muscle to pull a $5bn acquisition...
International Edition